Rallybio Corp

NASDAQ RLYB

Data sourced from

and

Download Data

Rallybio Corp Days Payable Outstanding (DPO) 3 year CAGR for the year ending December 31, 2023: -36.54%

Rallybio Corp Days Payable Outstanding (DPO) 3 year CAGR is -36.54% for the year ending December 31, 2023. The days payables outstanding ratio measures the average number of days it takes for a company to pay its suppliers. It is calculated by dividing accounts payable by the cost of revenue and then multiplying by 365. This ratio indicates the average payment period for suppliers and reflects the efficiency of managing trade payables. A longer period suggests extended payment terms and potential working capital advantages. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Rallybio Corp Days Payable Outstanding (DPO) for the year ending December 31, 2022 was 2,434.79, a 20.58% change year over year.
Rallybio Corp Days Payable Outstanding (DPO) for the year ending December 31, 2021 was 2,019.22, a -78.27% change year over year.
Rallybio Corp Days Payable Outstanding (DPO) for the year ending December 31, 2020 was 9,291.23.

NASDAQ: RLYB

Rallybio Corp

CEO	Dr. Martin W. MacKay Ph.D.
IPO Date	July 29, 2021
Location	United States
Headquarters	234 Church Street, New Haven, CT, United States, 06510
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Key trends